Massive vaccine trial aims to stop debilitating chikungunya virus

NCT ID NCT07467707

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Bavarian Nordic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests a new vaccine to prevent chikungunya, a virus that causes fever and severe joint pain. About 6,144 people aged 12 and older will receive either the vaccine or a placebo. Researchers will check if the vaccine safely prevents infection and reduces long-term joint problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Kamphaeng Phet Provincial Hospital
RECRUITING

Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand

Contact
Songklanagarind hospital, Prince of Songkla University (PSU)
NOT_YET_RECRUITING

Hat Yai, Changwat Songkhla, 90110, Thailand

Contact
WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC)
RECRUITING

Cebu City, Cebu, 6000, Philippines

Contact